Layer 01 · Status
Clinical
Approved narcolepsy product with a contingent second-indication kicker that could double the rate.
Layer 02 · Who pays?
Royalty stack
Tiered, indication-contingent rates plus a contingent value right tied to a Phase 3 readout. Standard databases miss most of this.
Narcolepsy royalty
3.85%
Reducible to 3.75% on net sales through Feb 2036. Jazz pays Avadel/Alkermes on net narcolepsy sales.
Future-indication royalty
10%
Reducible to 9.5%. On any approved indications including idiopathic hypersomnia (IH) from no earlier than March 2028.
The 10% IH-contingent rate is the interesting structural feature. A standard royalty database flags this asset as "3.85% narcolepsy royalty" and stops. The 10% kicker plus the IH probability is what determines whether the royalty is worth acquiring.
Base rate (navy) is contractual. The IH kicker (gold) crystallises only on indication-specific approval from March 2028.
Layer 03 · Fair rate?
Rate comparables
Sleep / CNS comps, plus indication-contingent step-up structures.
The 3.85% base rate sits below the median CNS approved-asset comp (4.8%) but the contingent 10% IH kicker, if it triggers, places the blended rate well above median. The structure matches what we see in roughly 12% of the indication-contingent deals in our corpus, almost all of them post-2020.
Layer 04 · Triggers
Milestones & events
What CFC saw before the market — recent inputs that move the deal.
- Oct 2025 $90M Jazz to Avadel settlement closes outstanding patent litigation
- Feb 2026 Alkermes acquires Avadel at $18.50/share + $1.50 CVR contingent on IH approval by end-2028, total ~$2.1B
- Jul 2025 Takeda oveporexton (TAK-861) Phase 3 hits in narcolepsy; H2 2026 launch expected. CFC competitive rating upgraded Watch → High.
Layer 05 · Threats
Competitors
Why the IH probability and the oveporexton timing both matter for the same royalty.
Oveporexton is the structural threat to the narcolepsy base. If it launches H2 2026 and captures 25% of new patient starts within two years, our model knocks ~30% off LUMRYZ peak narcolepsy royalty. That makes the IH kicker proportionally more valuable, not less, to anyone underwriting today.
Layer 06 · Value
What CFC saw before the market
Three calibration anchors the engine produced for this stack ahead of the Alkermes transaction.
Settlement risk priced
Jazz–Avadel litigation overhang resolved at $90M in October 2025. Without that overhang, an acquirer underwrites a narrower band of legal risk and can pay materially more.
IH kicker dominates
At a market-implied ~40% IH approval probability by end-2028, the 10% kicker contributes a meaningful slice of fair value. Below 25% and the royalty trades like a narcolepsy-only asset.
Oveporexton-resistant
The IH indication is structurally less exposed to oveporexton's narcolepsy-first launch path, which makes the IH kicker partially uncorrelated with the base-rate erosion risk.
Complex royalty stacks are not the exception. They are most of the market.
The single line "3.85% narcolepsy royalty" describes the asset only at first glance. The full picture, including indication-contingent tiers, litigation history, and competitive substitution, is what determines whether the position is worth acquiring at any given price.